Risk Factors for Breakthrough Cytomegalovirus Infections While on Prophylaxis in Kidney and Pancreas Transplant Recipients
Transplant Infectious Disease · 2026-05 · 28 (3)
DOI: 10.1111/tid.70184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 17.02.2026. Verfasst von Kayla Moody und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Duke University Hospital, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Kidney Transplantation, Pancreas Transplantation, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center For Advancing Translational Sciences of the National Institutes of Health.
Abstract (Originalsprache)
Background
Breakthrough cytomegalovirus (CMV) infection during antiviral prophylaxis may result in significant morbidity. The purpose of this study was to identify the incidence of breakthrough CMV infection and subsequent risk factors in kidney and pancreas transplant recipients on antiviral prophylaxis.
Methods
This single‐center retrospective cohort study examined 408 adult kidney and/or pancreas transplant episodes from 2018 to 2021 that received CMV antiviral prophylaxis after transplant. Multivariable Cox regression analysis was utilized to explore the association between breakthrough infection and previously identified risk factors, such as delayed graft function (DGF) and rejection.
Results
Breakthrough CMV infection occurred in 125/408 (30.8%) of patients. The median time to detection was 30 days after transplant (IQR: 18–50). Those with breakthrough infection had higher incidence of DGF, longer cold ischemic time, and were more commonly deceased donor transplant recipients. Multivariable Cox regression analysis showed DGF was a significant risk factor for breakthrough infection with an HR of 1.68 (95% CI [1.15, 2.45], p < 0.01).
Conclusion
Ensuring appropriate dosing of prophylaxis in the setting of DGF may result in decreased risk of breakthrough CMV infection and further complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Duke University Hospital, Durham, North Carolina, USA.
- Department of Biostatistics and Informatics, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Kayla Moody, Matt Harris
Förderung
- NCATS NIH HHS
- National Center For Advancing Translational Sciences of the National Institutes of Health
Zitieren
APA
Moody, K., Byrns, J., Yang, L. Z., Zhang, S., Erkanli, A., & Harris, M. (2026). Risk Factors for Breakthrough Cytomegalovirus Infections While on Prophylaxis in Kidney and Pancreas Transplant Recipients. Transplant Infectious Disease, 28(3). https://doi.org/10.1111/tid.70184
Vancouver
Moody K, Byrns J, Yang LZ, Zhang S, Erkanli A, Harris M. Risk Factors for Breakthrough Cytomegalovirus Infections While on Prophylaxis in Kidney and Pancreas Transplant Recipients. Transplant Infectious Disease. 2026;28(3). doi:10.1111/tid.70184
BibTeX
@article{Moody2026,
author = {Moody, Kayla and Byrns, Jennifer and Yang, Lexie Zidanyue and Zhang, Songyun and Erkanli, Alaattin and Harris, Matt},
title = {Risk Factors for Breakthrough Cytomegalovirus Infections While on Prophylaxis in Kidney and Pancreas Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {3},
doi = {10.1111/tid.70184}
}
EUVIMED